Evaluation of fluorescence-guided surgery agents in a murine model of soft tissue fibrosarcoma JOURNAL OF SURGICAL ONCOLOGY Prince, A. C., McGee, A. S., Siegel, H., Rosenthal, E. L., Behnke, N. K., Warram, J. M. 2018; 117 (6): 1179–87


Soft tissue sarcomas (STS) are mesenchymal malignancies. Treatment mainstay is surgical resection with negative margins?±?adjuvant treatment. Fluorescence-guided surgical (FGS) resection can delineate intraoperative margins; FGS has improved oncologic outcomes in other malignancies. This novel strategy may minimize resection-associated morbidity while improving local tumor control.We evaluate the tumor-targeting specificity and utility of fluorescence-imaging agents to provide disease-specific contrast. Mice with HT1080 fibrosarcoma tumors received one of five probes: cetuximab-IRDye800CW (anti-EGFR), DC101-IRDye800CW (anti-VEGFR-2), IgG-IRDye800CW, the cathepsin-activated probe Prosense750EX, or the small molecule probe IntegriSense750. Tumors were imaged daily using open- and closed-field fluorescence imaging systems. Tumor-to-background ratios (TBR) were evaluated. On peak TBR days, probe sensitivity was evaluated. Tumors were stained and imaged microscopically.At peak, closed-field imaging TBR of cetuximab-IRDye800CW (16.8) was significantly greater (P?

View details for PubMedID 29284070